Marije Van Schalkwyk
Overview
Explore the profile of Marije Van Schalkwyk including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
205
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Torres T, Saha P, Smeaton L, Wimbish C, Kliemann D, Avihingsanon A, et al.
Qual Life Res
. 2025 Feb;
PMID: 40019678
Background: Direct-acting antivirals (DAA) are highly effective for the management of HCV disease. This study aims to evaluate changes in health-related quality of life (HQoL) among people with HCV who...
2.
Lumley S, Kent C, Jennings D, Chai H, Airey G, Waddilove E, et al.
Sci Rep
. 2025 Feb;
15(1):5795.
PMID: 39962085
Hepatitis B virus (HBV) whole genome sequencing (WGS) is currently limited as the DNA viral loads (VL) of many clinical samples are below the threshold required to generate full genomes...
3.
Delphin M, Mohammed K, Downs L, Lumley S, Waddilove E, Okanda D, et al.
Lancet Gastroenterol Hepatol
. 2024 Feb;
9(4):383-392.
PMID: 38367632
The WHO African region bears a disproportionate burden of morbidity and mortality related to chronic hepatitis B virus (HBV) infection and accounts for an estimated 70% of new HBV infections...
4.
Van Schalkwyk M, Bekker A, Decloedt E, Wang J, Theron G, Cotton M, et al.
Antimicrob Agents Chemother
. 2023 Oct;
67(11):e0073723.
PMID: 37882552
Physiological changes during pregnancy may alter the pharmacokinetics (PK) of antituberculosis drugs. The International Maternal Pediatric Adolescent AIDS Clinical Trials Network P1026s was a multicenter, phase IV, observational, prospective PK...
5.
Agyemang N, Scarsi K, Baker P, Smeaton L, Podany A, Olefsky M, et al.
Pharmacogenet Genomics
. 2023 Jun;
33(6):126-135.
PMID: 37306344
Objective: In AIDS Clinical Trials Group study A5375, a pharmacokinetic trial of levonorgestrel emergency contraception, double-dose levonorgestrel (3 mg, versus standard dose 1.5 mg) offset the induction effects of efavirenz...
6.
Mofokeng N, Maponga T, Van Schalkwyk M, Hugo S, Morobadi M, Vawda S, et al.
J Virus Erad
. 2023 Mar;
9(1):100317.
PMID: 36911657
High profile international goals have been set for the elimination of hepatitis B virus (HBV) infection as a public health threat by the year 2030. Developing and expanding equitable, accessible...
7.
Mcinziba A, Wademan D, Viljoen L, Myburgh H, Jennings L, Decloedt E, et al.
AIDS Care
. 2023 Feb;
35(10):1628-1634.
PMID: 36781407
Current antiretroviral therapy (ART) adherence monitoring is premised on patients' self-reported adherence behaviour (prone to recall error) and verified by blood viral load measurement (which can delay results). A newly...
8.
van Zyl G, Jennings L, Kellermann T, Nkantsu Z, Cogill D, Van Schalkwyk M, et al.
AIDS
. 2022 Oct;
36(14):2057-2062.
PMID: 36305182
Objective: Access to viral load measurements is constrained in resource-limited settings. A lateral flow urine tenofovir (TFV) rapid assay (UTRA) for patients whose regimens include TFV offers an affordable approach...
9.
Avihingsanon A, Hughes M, Salata R, Godfrey C, McCarthy C, Mugyenyi P, et al.
J Int AIDS Soc
. 2022 Aug;
25(6):e25905.
PMID: 36039892
Introduction: ACTG A5288 was a strategy trial conducted in diverse populations from multiple continents of people living with HIV (PLWH) failing second-line protease inhibitor (PI)-based antiretroviral therapy (ART) from 10...
10.
Solomon S, Wagner-Cardoso S, Smeaton L, Sowah L, Wimbish C, Robbins G, et al.
Lancet Gastroenterol Hepatol
. 2022 Jan;
7(4):307-317.
PMID: 35026142
Background: Despite widespread availability of direct-acting antivirals including generic formulations, limited progress has been made in the global adoption of hepatitis C virus (HCV) treatment. Barriers to treatment scale-up include...